Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCTRLN)

Drug Name

OT-101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2/3	[1]
Merkel cell carcinoma	2C34	Phase 2/3	[1]
Pancreatic cancer	2C10	Phase 2/3	[2]
Recurrent glioblastoma	2A00.00	Phase 2/3	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting TGF beta-2 messenger RNA (TGFB2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belagenpumatucel-L	DMQG7ZM	Non-small-cell lung cancer	2C25.Y	Phase 3	[5]
Ranagengliotucel-T	DMNTURD	Brain cancer	2A00	Discontinued in Phase 3	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TGF beta-2 messenger RNA (TGFB2 mRNA)	TTI0KH6	TGFB2_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT04801017) A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of Oncotelic.
5	National Cancer Institute Drug Dictionary (drug id 590662).
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210)